>>Signaling Pathways>> Tyrosine Kinase>> VEGFR>>SU5408 (VEGFR2 Kinase Inhibitor I)

SU5408 (VEGFR2 Kinase Inhibitor I) (Synonyms: SU 5408)

Catalog No.GC32469

SU5408(VEGFR2 키나제 억제제 I)(VEGFR2 키나제 억제제 I)은 70nM의 IC50을 갖는 VEGFR2 키나제의 강력한 세포 투과성 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

SU5408 (VEGFR2 Kinase Inhibitor I) Chemical Structure

Cas No.: 15966-93-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$245.00
재고 있음
1mg
US$82.00
재고 있음
5mg
US$358.00
재고 있음
10mg
US$681.00
재고 있음
25mg
US$1,517.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SU5408 is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC50 of 70 nM.

3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50>100 µM)[1].

[1]. Sun L, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity towardparticular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603.

리뷰

Review for SU5408 (VEGFR2 Kinase Inhibitor I)

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SU5408 (VEGFR2 Kinase Inhibitor I)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.